Reig Jofre surpasses with grow the figures of the same period of 2022. The laboratory founded in 1929 in Barcelona has achieved some sales that have reached the 157 million euros in this first semester of 2023. Like this it has communicated it the same company through a press release in which it also has signalled the increase of the EBITDA 25%, arriving to the 17,8 million euros.
The pharmaceutical laboratory has explained that the sales find 19% above the same period of time that in 2022. The division that more has grown in Reig Jofre in these first six months of year has been Speciality Pharmcare, that supposes 31% of the total income aimed in the game of this first semester. The segment Pharmaceutical Technologies, by his part, is the most notable division in volume of sales and in which they include products inyectables and antibiotics. Consumer Healthcare Is the segment of products of consumption under the mark FORTE PHARMA and this also has experienced a growth in his sales of 14%, especially in the markets of Spain, France and Belgium.
As it has indicated Europe Press, Spain supposes 46% of the sales of the pharmaceutical laboratory Catalan. The rest of European markets add 41% of remaining sales, between which stands out the backstitch of Poland. The number of sales in the European market has grown 7% and has been especially thanks to the interest and to the increase of the demand by part of the Polish market.
The rest of countries accumulate 13% remaining of the sales, that has grown 45% thanks to the impulse of the division of Pharmaceutical Technologies by the interest of the Asian markets, that have turned into 9% of income by the group of the first semester.
Reig Jofre the past 2022 closed the year with a total of 271 million euros in income, 15% more with regard to the previous year in which only it had grown 3%. To the equal that in these first six months of year, the segment of the company that more increased his demand was the one of Pharmaceutical Technologies. The EBITDA of then grew 11% and reached more than 30 million euros, 3 millions more than in the 2021.